engleski

Multidrug resistant Acinetobacter baumannii – a decade of the successful clone in Croatia

Among the “ESKAPE“ group of serious pathogens Acinetobacter baumannii is under a great concern worldwide. This microorganism has become a leading nosocomial pathogen of the 21th century, and numerous studies are focused on the epidemiology, resistance and control measures of this pathogen in the hospital setting. The epidemiology and molecular basis of resistance of clinical isolates of Acinetobacter baumannii in Croatia over the last two decades has changed significantly in most health institutions, with a high percentage of resistance to carbapenems, quinolones and aminoglycosides, and the presence of multiresistant isolates. Research into the resistance of this microorganism as an important hospital pathogen began in Croatia in 2002. on isolates from UHC Split, where the basis of reduced susceptibility to carbapenems was studied molecularly. Genotyping of the first clinical isolates with reduced susceptibility to one or both carbapenems proved the presence of European clone 1 (later called International IC1) from 2002. to 2008. In early 2009., an epidemic spread of a new clone belonging to IC2 occurred. The characteristics of A. baumannii belonging to the new clone are easy to detect in routine susceptibility testing as this isolate shows resistance to both carbapenem antibiotics with high levels of minimum inhibitory concentrations (MIC> 32 mg/L) on imipenem and meropenem. This new clone belonging to IC2 with confirmed epidemiological transmission from neighboring Bosnia and Herzegovina, also referred to as the Mostar Clone in its first published citations, is today predominantly present in most healthcare institutions in Croatia. In epidemiological terms, this new clone completely suppressed isolates belonging to IC1 from 2002. and has become dominant clone in almost all health care institutions in Croatia.

Acinetobacter baumannii, Croatia

nije evidentirano